Evidence map›Paper›PMID 39629239›Full record

ArticleFrontiers in medicine2024

Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial.

Connor Prosty, Michelle Le, Yang Lu, Lauren Khoury, Maxime Cormier, Mathew P Cheng, Robert Fowler, Srinivas Murthy, Jennifer Ly Tsang, Duncan Lejtenyi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Connor Prosty *Faculty of Medicine, McGill University, Montreal, QC, Canada.
Michelle Le *Division of Dermatology, Department of Medicine, McGill University, Montreal, QC, Canada.
Yang LuDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Lauren KhouryFaculty of Medicine, McGill University, Montreal, QC, Canada.
Maxime CormierDivision of Respiratory Medicine, Department of Medicine, McGill University, Montreal, QC, Canada.
Mathew P ChengDivision of Infectious Diseases, Department of Medicine, McGill University, Montreal, QC, Canada.
Robert FowlerDepartment of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Srinivas MurthyDepartment of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Jennifer Ly TsangNiagara Health Knowledge Institute, Niagara Health, St. Catharines, ON, Canada.
Duncan LejtenyiDivision of Allergy, Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, QC, Canada.
Moshe Ben-ShoshanDivision of Allergy, Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, QC, Canada.
Elham RahmeDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Shirin GolchiDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Nandini DendukuriDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Todd C LeeDivision of Infectious Diseases, Department of Medicine, McGill University, Montreal, QC, Canada.
Elena NetchiporoukFaculty of Medicine, McGill University, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The CIAO trial recently demonstrated a probable clinical benefit of omalizumab in the treatment of severe COVID-19; however, the mechanism underlying this benefit remains unclear. Therefore, we sought to longitudinally assess the impact of omalizumab on serum cytokines in CIAO trial patients to determine its mechanism of action. Methods: Blood samples were collected on days 0, 2, 7, and 14 from patients recruited into the CIAO trial and who consented to this substudy. Blood samples were tested by a panel of 25 inflammatory cytokines, as well as for markers of mast cell activation. Levels of inflammatory biomarkers were compared over time between omalizumab- and placebo-treated patients by generalized linear mixed-effects model. Associations between biomarkers and clinical outcomes were investigated by mixed-effects logistic regression. Results: Nineteen patients were recruited into this substudy; 10 were assigned to placebo and 9 to omalizumab. Monokine induced by gamma interferon was significantly positively associated with severe COVID-19 (Odds Ratio [OR] = 1.06, 95%CI = 1.00-1.11, Conclusion: Although limited by a small sample size, these results suggest that omalizumab's potential benefit in COVID-19 may be mediated independently of modulation of the measured serum biomarkers. Further studies are needed to investigate omalizumab's mechanism of action in COVID-19.

Indexed as

clinical trialcoronavirusCOVID-19cytokineomalizumab

Identifiers

PMID39629239
PMCPMC11611588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.